Patents
Sitemap › C07 - Organic chemistry › C07K - Peptides › C07K 7 - Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
Patents for C07K 7 - Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof (42,273)
10/2007
10/25/2007WO2007118693A1 Process for the manufacture of lysobactin derivatives
10/25/2007WO2007118691A1 Lysobactin amides
10/25/2007WO2006110185A3 Antiinfective lipopeptides
10/25/2007US20070249806 Solid phase Fmoc chemistry process to prepare peptides
10/25/2007US20070249531 Method for the Detection of Autoantibodies Against Specific Peptides and Its Use in Diagnosis and Treatment of Pregnancy-Loss or Infertility
10/25/2007US20070249527 autoimmune diseases; antiarthritic agents; inflammatory bowel disorders; psoriasis; antiallergens; chronic obstructive pulmonary disease; antiallergens
10/25/2007US20070249526 Process for the preparation of cyclic peptides
10/25/2007US20070249521 polypeptide having antimicrobial activity, having an amino acid sequence selected from e.g. Arg Arg Arg Pro Pro Arg Leu Pro Arg Pro Phe Pro; Phe Arg Pro Pro Pro Arg Pro Arg Pro Leu Pro Val; detergents, animal feed
10/25/2007US20070249061 Screening method of new drug candidates using protein interaction happening after binding a small amount of protein on high sensitive protein chip; can be used for research of protein-protein interactions; peptide composition for treating cancer
10/25/2007US20070248972 Page-4, an X-linked gage-like gene expressed in normal and neoplastic prostate, testis and uterus, and uses therefor
10/25/2007US20070248615 T helper cell epitopes
10/25/2007US20070248583 Novel Strains Belonging to the Genus Paenibacillus and Method of Controlling Plant Disease by Using These Strains or Culture Thereof
10/25/2007CA2649360A1 Mono and di-substituted oxycodone compounds and compositions
10/25/2007CA2649303A1 Homogeneous erythropoietin and other peptides and proteins, methods and intermediates for their preparation
10/25/2007CA2649114A1 Compositions and methods for modulating gene expression
10/25/2007CA2648164A1 Lysobactin amides
10/25/2007CA2648136A1 Process for the manufacture of lysobactin derivatives
10/24/2007EP1847550A2 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
10/24/2007EP1846438A2 Methods and means for use in diagnostics and treatment of diabetes
10/24/2007EP1846437A1 ACID ADDITION SALTS OF Ac-PHSCN-NH2
10/24/2007EP1846016A2 Methods of increasing cerebral blood flow
10/24/2007EP1432728A4 Methods and compositions for treating inflammatory disorders
10/24/2007EP1311281B1 Antimicrobial sulfonamide derivatives of lipopeptide antibiotics
10/24/2007EP1121431B9 Non-endogenous, constitutively activated human g protein-coupled receptors
10/24/2007CN101059510A New assays for preimplantation factor and preimplantation factor peptides
10/24/2007CN101058601A Horseshoe crab anti-endotoxin factor analogue peptide molecule, synthetic method and use thereof
10/24/2007CN100344648C Cyclosporine analogue mixtures and their use as immunomodulating agents
10/23/2007US7285634 Used to screen for antagonists and agonists of IL-1R AcP signal transduction and as therapeutics for diseases mediated by IL-1 family members
10/23/2007US7285622 Hydrophilic polymer covalently yet reversibly linked to a amine-containing ligand through a dithiobenzyl linkage; modification of various substrates, such as polypeptides
10/23/2007US7285621 Multiple branch peptide construction
10/23/2007US7285619 E.g, 1-([-4-oxo-N2-(12-methyl-1-oxotetradecyl)-L-ornithine]-4-[4-(4-hydroxyphenyl)-L-threonine]-5-L-serine-echinocandin B and 1-[N2-[[4'-octyloxy)-[1,1'-biphenyl]-4-yl]-carbonyl]-4-oxo-L-ornithine]-4-[4-(4-hydroxyphenyl)-L-threonine]-5-L-serine-echinocandin B
10/23/2007US7285535 Administering TIRAP to block Toll/Interleukin-1 Receptor Adaptor Protein signaling in a cell; for treatment of inflammation and inducing or affecting immune response.
10/23/2007US7285528 Peptide antagonists of GnRH-2 that bind to GnRH-2 receptors; useful for the treatment of reproductive diseases and steroid-related cancers
10/23/2007US7285282 Mucin peptide with immunoenhancing properties
10/23/2007CA2191612C A process for preparing cardiodilatin fragments; highly purified cardiodilatin fragments and intermediate products for the preparation of same
10/23/2007CA2111325C Detection of mammalian immunodeficiency viruses
10/18/2007WO2007117564A2 Clay-binding peptides and methods of use
10/18/2007WO2007045243A3 Novel fgf receptor binding compounds comprising peptide fragments of neural cell adhesion molecule l1
10/18/2007WO2002088707A3 Biopolymer marker having a molecular weight of 1998 daltons
10/18/2007US20070244316 Optically pure and enriched isomers of chelating ligands and contrast agents
10/18/2007US20070244055 Conjugates useful in the treatment of prostate cancer
10/18/2007US20070244054 Peptides for use in treating obesity
10/18/2007US20070244050 Peptides as solubilizing excipients for transforming growth factor beta proteins
10/18/2007US20070243554 Carbon nanotube binding peptides
10/18/2007US20070243206 Using hybrid fibrin peptides to prevent hemophilus infection
10/18/2007US20070243139 A dimer of two polypeptides having specificity andreceptivity for different epitopes on a protein-tyrosinekinase receptor; linked by spacers; synergistic; contrast agents for radition imaging and therapy; biodrugs; hepatocyte growth factor receptor/cMET complex target; antitumor, -carcinogenic agents
10/18/2007DE102006018080A1 Lysobactinamide Lysobactinamide
10/18/2007CA2648403A1 Soluble virus-specific t-cell receptor compositions
10/18/2007CA2638778A1 Clay-binding peptides and methods of use
10/18/2007CA2616859A1 Compositions and methods for production of immunoglobulins
10/17/2007EP1845106A1 Low molecular weight peptide derivatives as inhibitors of the laminin/nidogen interaction
10/17/2007EP1844789A1 Emulsified composition for dilution and cancer vaccine composition
10/17/2007EP1844337A1 Binding compounds, immunogenic compounds and peptidomimetics
10/17/2007EP1844070A1 Peptides with neuropeptide-2 receptor (y2r) agonist activity
10/17/2007EP1427758B1 Compositions and methods of treating diabetes
10/17/2007EP1123387B1 Mn gene and protein
10/17/2007CN101056886A Molecules which promote hematopoiesis
10/17/2007CN101056884A Peptide cyclisation
10/17/2007CN101054410A Antigen epitope III of neutrality B cell of chicken IBDV VP2 protein and application thereof
10/17/2007CN101054409A Amphiphilic short peptide and use thereof
10/17/2007CN100343278C Thymus gland pentapeptide purification technique
10/17/2007CN100343276C Bone formation stimulant, synthetic method and uses thereof
10/17/2007CN100343264C Process for producing sugar chain asparagine derivative
10/16/2007USRE39887 A cyclic depsipeptide from a tunicate of the Ascidiacea class; viricides, antitumor agents, immunosuppressants and cytotoxic agents
10/16/2007US7282476 Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer
10/13/2007CA2566832A1 Cyclised alpha-conotoxin peptides
10/11/2007WO2007115180A1 Fullerene assisted cell penetrating peptides
10/11/2007WO2007114307A1 Mucin-type glycopeptide having polylactosamine backbone
10/11/2007WO2007113386A1 Peptide conjugates
10/11/2007WO2007113385A1 Diagnostic and therapeutic agents
10/11/2007WO2007112566A1 Compositions and methods for treating atherosclerosis
10/11/2007WO2007112492A1 Compounds and methods for the treatment of pain
10/11/2007WO2007096859A3 Protection of the retina against laser injury by adnf peptides such as nap and sal
10/11/2007WO2007087851A8 Method for producing epitomers and their uses on carrier microorganisms
10/11/2007US20070238670 Placing an early endosome toxin selected from Diptheria toxin, Botulinum, Anthrax toxin Lethal Factor, and Anthrax toxin Edema Factor; placing in a cytosolic buffer; contacting with a cytosolic translocation factor complex, comprising beta-COP; acidification, measurement; drug screening; antiapoptosis
10/11/2007US20070238669 Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes related conditions
10/11/2007US20070238666 Cancer treatment by administration of a synthetic peptide comprising a sequence of amino acids within the p53 protein and a membrane penetrating leader sequence
10/11/2007US20070238197 Fluorescent ligands for GPCR arrays
10/11/2007DE102006015140A1 Heterozyklische Verbindungen mit Wirkung gegen neurodegenerative Erkrankungen Heterocyclic compounds with activity against neurodegenerative diseases
10/11/2007CA2647775A1 Synthetic peptides useful in the treatment of the skin and use thereof in cosmetic or dermopharmaceutical compositions
10/11/2007CA2645245A1 Compositions and methods for treating atherosclerosis
10/10/2007EP1842911A1 Hla-binding peptides, dna fragments encoding the same and recombinant vectors
10/10/2007EP1842859A2 Monoclonal antibody specific for beta A4 peptide
10/10/2007EP1841882A1 Protein phosphorylation in egfr-signaling pathways
10/10/2007EP1841446A1 Peptides and compounds that bind to the il-5 receptor
10/10/2007EP1624897B1 Hiv prodrugs cleavable by cd26
10/10/2007EP1385882B1 Peptides and related molecules that bind to tall-1
10/10/2007EP1272215B1 Pharmaceutical preparations comprising modified peptides
10/10/2007EP1090924B1 Tumor antigen peptides originating in cyclophilin b
10/10/2007EP0975792B1 Isolation of tissue specific peptide ligands and their use for targeting pharmaceuticals to organs
10/10/2007CN101052651A Caspase-2 inhibitors and their biological applications
10/10/2007CN101052650A Novel peptide for treating obesity
10/10/2007CN101052649A Peptide for treating obesity
10/10/2007CN101052647A Novel peptide for treating obesity
10/10/2007CN101052408A Peptides that selectively home to heart vasculature and related conjugates and methods
10/10/2007CN100341889C Antigen epitope II of B cell of chicken IBDV VP3 protein
10/10/2007CN100341573C Synergistic compositions for the prevention and treatment of acquired immunodeficiency syndrome
10/09/2007US7279549 Apha-conotoxin peptides
10/09/2007US7279502 Such as prostate cancer, prostatitis and benign prostatic hyperplasia; ethyl endcapped hepta- and nona-tetramethylenediamines and 1,2-bis(4-(ethylamino)butylaminomethyl)cyclopropane
10/09/2007US7279458 Glycopeptide group is covalently linked to a pyridinium moiety of a cephalosporin group; reacting a glycopeptide containing (c6.c6.c6.c6.c6.c10n2.c13n2o.c13n2o ring) with a cephalosporin or salt in presence of a diacid
1 ... 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 ... 423